QWQingyi Wei

Qingyi Wei

*This is an algorithmically generated author record based on publicly available information.

Qingyi Wei has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis

    by Lie Cheng, Margaret R. Spitz, Waun K. Hong, Qingyi Wei

    Epidemiological studies have indicated that reduced DNA repair capacity and increased DNA adduct levels are associated with increased risk of lung cancer. Nucleotide excision repair (NER) is the major pathway in humans for repairing DNA adducts induced by smoking-related carcinogens, such as benzo[a]pyrene diol epoxide. We hypothesized that genetically determined baseline expression level of genes involved in NER is associated with risk of lung cancer. In a pilot case-control study, we measured the relative expression levels of five NER genes [ERCC1, XPB/ERCC3, XPG/ERCC5, CSB/ERCC6 and XPC (ERCC, excision repair cross-complementing; CSB, Cockayne's syndrome complementary group B)] in phytohemagglutinin-stimulated peripheral lymphocytes obtained from 75 lung cancer patients and 95 controls using a newly developed multiplex RT–PCR assay. Cases and controls were matched on age, sex, ethnicity and tobacco use. The expression level of the β-actin gene was used as an internal control for the relative quantitation. We observed a 12.2 and 12.5% decrease in the baseline expression levels of XPG/ERCC5 and CSB/ERCC6, respectively, in cases compared with controls. These differences were statistically significant (P < 0.01) when the median expression level in the controls was used as the cut-off point, the lung cancer patients were significantly more likely than the controls to have reduced expression levels of XPG/ERCC5 [odds ratio (OR), 2.32; 95% confidence interval (CI), 1.22–4.43] and CSB/ERCC6 (OR, 2.49; 95% CI, 1.28–4.84). There was also a dose–response relationship between reduced expression levels and increased lung cancer risk (trend test: P < 0.01). Our results suggest that individuals whose expression levels of XPG/ERCC5 and CSB/ERCC6 are reduced may be at higher risk of lung cancer.


  • Open Access

    Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck

    by Lie Cheng, Erich M. Sturgis, Susan A. Eicher, David Char, Margaret R. Spitz, Qingyi Wei

    Differences in genetic susceptibility to tobacco‐induced carcinogenesis appear to modulate an individual's risk of squamous‐cell carcinoma of the head and neck (SCCHN). Risk for SCCHN may be associated with the null alleles of the carcinogen‐metabolizing genes glutathione‐S‐transferase (GST) T1 and GSTM1. In this study, we evaluated the association between GSTM1 and GSTT1 null genotypes and risk of SCCHN in a matched case‐control study of 162 patients with SCCHN and 315 healthy controls. Our results showed that 53.1% of cases and 42.9% of controls were null for GSTM1, whereas 32.7% of cases and 17.5% of controls were null for GSTT1 (p < 0.05 and p < 0.001, respectively). Furthermore, 19.8% of cases but only 7.9% of controls were null for both genes (p < 0.001). Multivariate analysis using logistic regression models, including age, sex, ethnicity, smoking status, alcohol status and GST genotypes, showed that both of these genotypes remained independent risk factors for disease [adjusted odds ratios (ORs) = 1.50 and 2.27, respectively; 95% confidence intervals (CIs) = 1.01–2.23 and 1.43–3.60, respectively). When the genotypes were divided into neither null, either null or both null, there was a dose‐response relationship (adjusted OR = 1.50, 95% CI = 0.98–2.30) for the either‐null group and (adjusted OR = 3.64, 95% CI = 1.94–6.84) for the both‐null group (p < 0.001, trend test). Our findings suggest that the GSTM1 and GSTT1 null genotypes are independent risk factors for SCCHN and markers for genetic susceptibility to tobacco‐induced carcinogenesis. Int. J. Cancer (Pred. Oncol.) 84:220–224, 1999.


  • Open Access

    Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas

    by Randa El-Zein, Melissa L. Bondy, Li-E Wang, Mariza de Andrade, Alice J. Sigurdson, Janet M. Bruner, Athanassios P. Kyritsis, Victor A. Levin, Qingyi Wei

    Brain tumors exhibit considerable chromosome instability (CIN), suggesting that genetic susceptibility may contribute to brain tumorigenesis. To test this hypothesis, in this pilot study, we examined for CIN in short-term lymphocyte cultures from 25 adult glioma patients and 28 age-, sex- and ethnicity-matched healthy controls (all Caucasian). We evaluated CIN by a multicolor fluorescence in situ hybridization assay using two probes: a classic satellite probe for a large heterochromatin breakage-prone region of chromosome 1 and an alpha satellite probe for a smaller region adjacent to the heterochromatin probe. Our results showed a significant increase in the mean number of spontaneous breaks per 1000 cells in glioma patients (mean ± SD, 2.4 ± 0.8) compared with controls (1.4 ± 0.9; P < 0.001). By using the median number of breaks per 1000 cells in the controls as the cutoff value, we observed a crude odds ratio (OR) of 8.5 [95% confidence interval (CI) = 2.05–34.9, P < 0.001] for spontaneous breaks and brain tumor risk. After adjustment for age, sex and smoking status, the adjusted OR was 15.3 (95% CI, 2.71–87.8). A significant increase in cells with chromosome 1 aneuploidy (in the form of hyperdiploidy) (P < 0.001) was also observed in the glioma cases, with an adjusted OR of 6.6 (95% CI = 1.5–30, P < 0.05). These findings suggest that CIN can be detected in the peripheral blood lymphocytes of brain tumor patients and may be a marker for identifying individuals at risk.


  • Open Access

    DNA Repair in Lymphoblastoid Cell Lines From Patients With Head and Neck Cancer

    by Erich M. Sturgis, Gary L. Clayman, Yongli Guan, Zhaozheng Guo, Qingyi Wei

    APPROXIMATELY 46 million adult Americans smoke,1 yet only a small fraction (41,000) develop squamous cell carcinoma of the head and neck (SCCHN) annually.2 One would presume that differences in susceptibility to tobacco-induced carcinogenesis partially underlie the disparity between those exposed and those who ultimately develop cancer. Others have suggested that cancer susceptibility has an etiologic role in the development of SCCHN at a young age3 and in patients without tobacco or alcohol exposure.4